New Metabolites and Bioactive Actinomycins from Marine-Derived Streptomyces sp. ZZ338

Xiufang Zhang,Xuewei Ye,Weiyun Chai,Xiao-Yuan Lian,Zhizhen Zhang
DOI: https://doi.org/10.3390/md14100181
2016-10-11
Marine Drugs
Abstract:An extract prepared from the culture of a marine-derived actinomycete <i>Streptomyces</i> sp. ZZ338 was found to have significant antimicrobial and antiproliferative activities. A chemical investigation of this active extract resulted in the isolation of three known bioactive actinomycins (<b>1</b>-<b>3</b>) and two new metabolites (<b>4</b> and <b>5</b>). The structures of the isolated compounds were identified as actinomycins D (<b>1</b>), V (<b>2</b>), X<sub>0β</sub> (<b>3</b>), 2-acetylamino-3-hydroxyl-4-methyl-benzoic acid methyl ester (<b>4</b>), and <i>N</i>-1<i>S</i>-(4-methylaminophenylmethyl)-2-oxo-propyl acetamide (<b>5</b>) based on their nuclear magnetic resonance (NMR) and high resolution electrospray ionization mass spectroscopy (HRESIMS) data as well as their optical rotation. This class of new compound <b>5</b> had never before been found from a natural resource. Three known actinomycins showed activities in inhibiting the proliferation of glioma cells and the growth of methicillin-resistant <i>Staphylococcus aureus</i>, <i>Escherichia coli</i>, and <i>Candida albicans</i> and are responsible for the activity of the crude extract. Actinomycin D (<b>1</b>) was also found to downregulate several glioma metabolic enzymes of glycolysis, glutaminolysis, and lipogenesis, suggesting that targeting multiple tumor metabolic regulators might be a new anti-glioma mechanism of actinomycin D. This is the first report of such a possible mechanism for the class of actinomycins.
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?